[go: up one dir, main page]

MX2016014660A - Medios y metodos para el tratamiento de cmv. - Google Patents

Medios y metodos para el tratamiento de cmv.

Info

Publication number
MX2016014660A
MX2016014660A MX2016014660A MX2016014660A MX2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A
Authority
MX
Mexico
Prior art keywords
methods
cmv
pentameric
treating cmv
provides
Prior art date
Application number
MX2016014660A
Other languages
English (en)
Inventor
Wellnitz Sabine
John Corinne
Schaub Christian
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016014660A publication Critical patent/MX2016014660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la producción de proteínas recombinantes y la preparación de vacunas. En particular, la invención proporciona medios y métodos para la producción del complejo pentamérico gH/gL/UL128/UL130/UL131A de CMV. Más específicamente, la invención proporciona un complejo pentamérico gH/gL/UL128/UL130/UL131A de CMV producido en un sistema de baculovirus que puede ser utilizado como una vacuna contra el CMV.
MX2016014660A 2014-05-08 2015-05-08 Medios y metodos para el tratamiento de cmv. MX2016014660A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LU92450 2014-05-08
LU92452 2014-05-08
LU92449 2014-05-08
LU92451 2014-05-08
PCT/IB2015/053365 WO2015170287A1 (en) 2014-05-08 2015-05-08 Means and methods for treating cmv

Publications (1)

Publication Number Publication Date
MX2016014660A true MX2016014660A (es) 2017-02-28

Family

ID=53180768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014660A MX2016014660A (es) 2014-05-08 2015-05-08 Medios y metodos para el tratamiento de cmv.

Country Status (16)

Country Link
US (1) US20150322115A1 (es)
EP (1) EP3139953A1 (es)
JP (1) JP2017515503A (es)
KR (1) KR20170002560A (es)
CN (1) CN106460010A (es)
AU (1) AU2015257330A1 (es)
BR (1) BR112016025792A2 (es)
CA (1) CA2947938A1 (es)
IL (1) IL248803A0 (es)
MX (1) MX2016014660A (es)
PE (1) PE20170301A1 (es)
PH (1) PH12016502220A1 (es)
RU (1) RU2016147987A (es)
SG (1) SG11201608977UA (es)
TW (1) TW201609792A (es)
WO (1) WO2015170287A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
CA3019588A1 (en) * 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
BR112020004747A2 (pt) * 2017-09-13 2020-09-24 Sanofi Pasteur composição imunogênica de citomegalovírus humano
WO2019089410A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
CN108300731A (zh) * 2018-02-02 2018-07-20 暨南大学 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用
KR200492821Y1 (ko) 2018-08-10 2020-12-15 인제대학교 산학협력단 의료용 튜브 고정 기구
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
JP7179872B2 (ja) * 2018-12-10 2022-11-29 Ｋｍバイオロジクス株式会社 サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン
KR102837045B1 (ko) 2020-06-09 2025-07-23 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
KR102259156B1 (ko) 2020-09-28 2021-06-01 박나은 네트워크 환경 내 디바이스 인증 시스템 및 방법
EP4237085A1 (en) 2020-10-28 2023-09-06 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
WO2023223255A1 (en) 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
AU783246C (en) * 1999-12-14 2007-03-15 Asahi Kasei Kabushiki Kaisha Stabilizing diluent for polypeptides and antigens
US7629160B2 (en) 2004-12-21 2009-12-08 University Of Kentucky Research Foundation Vectors and methods for enhanced cell longevity and protein expression
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2012034025A2 (en) * 2010-09-09 2012-03-15 Virginia Commonwealth University Human cytomegalovirus vaccine
CA2814386C (en) * 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
WO2012106377A2 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
MX378747B (es) * 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
US20150359879A1 (en) * 2012-10-30 2015-12-17 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection

Also Published As

Publication number Publication date
PH12016502220A1 (en) 2017-01-09
BR112016025792A2 (pt) 2017-10-17
EP3139953A1 (en) 2017-03-15
PE20170301A1 (es) 2017-03-30
IL248803A0 (en) 2017-01-31
CA2947938A1 (en) 2015-11-12
JP2017515503A (ja) 2017-06-15
RU2016147987A (ru) 2018-06-13
CN106460010A (zh) 2017-02-22
KR20170002560A (ko) 2017-01-06
AU2015257330A1 (en) 2016-11-17
SG11201608977UA (en) 2016-11-29
TW201609792A (zh) 2016-03-16
WO2015170287A1 (en) 2015-11-12
US20150322115A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
PH12016502220A1 (en) Means and methods for treating cmv
EP4344741A3 (en) Aav vectors targeted to the central nervous system
MX2022001105A (es) Anticuerpos anti tigit.
EP3134510A4 (en) Recombinant listeria vaccine strains and methods of producing the same
EP3009505A4 (en) Recombinant strain producing l-amino acids, constructing method therefor and method for producing l-amino acids.
EP3256571A4 (en) Methods for producing virus for vaccine production
EP3113800A4 (en) Enhanced production of recombinant crm197 in e. coli
EP3294450A4 (en) PROCESS FOR PRODUCING MODIFIED CLAY, MODIFIED CLAY PRODUCED AND USE THEREOF
EP3207142A4 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
MY191539A (en) Streptococcal vaccine
IN2015KN00323A (es)
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
EP3178491A4 (en) Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
IN2014MU00455A (es)
EP3237441A4 (en) Methods of improving yield in recombinant protein production
EP3106516A4 (en) Recombinant microorganism of genus escherichia with l-threonine productivity, and method for producing l-threonine using same
MX2016017367A (es) Dioxido de zirconio, producto refractario, uso de dioxido de zirconio, procedimiento para la fabricacion de un producto refractario asi como un producto refractario fabricado mediante el mismo.
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
PL3110756T3 (pl) Sposób otrzymywania modyfikowanej krzemionki, modyfikowana krzemionka i jej zastosowania, w szczególności do wzmacniania polimerów
EP3119874A4 (en) Microorganisms having enhanced l-amino acids productivity and process for producing l-amino acids using the same
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.
EP3168293A4 (en) Recombinant microorganism producing quinolinic acid and method for producing quinolinic acid using same
MX2018002020A (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
IN2014CH01391A (es)